Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials

Leuk Lymphoma. 2013 Oct;54(10):2310-3. doi: 10.3109/10428194.2013.772173. Epub 2013 Feb 28.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Benzamides / therapeutic use*
  • Dasatinib
  • Drug Substitution
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
  • Piperazines / therapeutic use*
  • Protein-Tyrosine Kinases / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Thiazoles / therapeutic use*
  • Treatment Failure
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Thiazoles
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases
  • Dasatinib